Symbols / IRIX $1.34 +4.69%
IRIX Chart
About
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 23.03M |
| Enterprise Value | 27.22M | Income | -5.09M | Sales | 50.65M |
| Book/sh | -0.08 | Cash/sh | 0.32 | Dividend Yield | — |
| Payout | 0.00% | Employees | 93 | IPO | — |
| P/E | — | Forward P/E | -19.14 | PEG | — |
| P/S | 0.45 | P/B | -17.40 | P/C | — |
| EV/EBITDA | -9.65 | EV/Sales | 0.54 | Quick Ratio | 1.22 |
| Current Ratio | 1.94 | Debt/Eq | 102.22 | LT Debt/Eq | — |
| EPS (ttm) | -0.30 | EPS next Y | -0.07 | EPS Growth | — |
| Revenue Growth | 7.80% | Earnings | 2026-03-24 | ROA | -6.53% |
| ROE | -139.29% | ROIC | — | Gross Margin | 38.18% |
| Oper. Margin | -11.30% | Profit Margin | -10.04% | Shs Outstand | 17.19M |
| Shs Float | 10.66M | Short Float | 0.53% | Short Ratio | 0.65 |
| Short Interest | — | 52W High | 1.65 | 52W Low | 0.78 |
| Beta | 0.65 | Avg Volume | 92.29K | Volume | 40.28K |
| Target Price | $3.00 | Recom | None | Prev Close | $1.28 |
| Price | $1.34 | Change | 4.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.00
Mean price target
2. Current target
$1.34
Latest analyst target
3. DCF / Fair value
$0.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.34
Low
$3.00
High
$3.00
Mean
$3.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-05-15 | main | Stifel | Hold → Hold | $2 |
| 2022-08-26 | down | Stifel | Buy → Hold | $3 |
| 2021-05-12 | main | Roth Capital | — → Buy | $11 |
| 2021-03-03 | main | Roth Capital | — → Buy | $9 |
| 2021-01-13 | main | Roth Capital | — → Buy | $6 |
| 2020-05-12 | main | Stifel | — → Buy | $4 |
| 2019-01-04 | main | Stifel | Buy → Buy | $7 |
| 2018-10-26 | init | Stifel | — → Buy | $9 |
| 2016-12-21 | init | Roth Capital | — → Buy | $20 |
| 2016-01-26 | init | Singular Research | — → Buy | $12 |
- Iridex CFO Dizon buys $1398 in IRIX stock - Investing.com Mon, 09 Mar 2026 17
- Insider Buying: Romeo Dizon Acquires Additional Shares of IRIDEX Corp (IRIX) - GuruFocus Mon, 09 Mar 2026 20
- Medical laser maker for glaucoma care turns cash positive after growth push - Stock Titan Mon, 12 Jan 2026 08
- IRIDEX (IRIX) Price Target Increased by 50.00% to 3.06 - Nasdaq ue, 24 Feb 2026 08
- Insider Purchase: Chief Financial Officer of $IRIX Buys 14,769 Shares - Quiver Quantitative Mon, 17 Nov 2025 08
- Valuation Update: Will IRIX stock go up in YEAR - July 2025 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn Fri, 06 Mar 2026 21
- IRIDEX (IRIX): Why This Micro-Cap Laser Stock Just Spiked – And What’s Next - AD HOC NEWS Sat, 21 Feb 2026 08
- Iridex Announces Plans to Relocate Headquarters - GlobeNewswire Mon, 02 Feb 2026 08
- Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 - GlobeNewswire Mon, 12 Jan 2026 08
- Insider Buying: Romeo Dizon Acquires Additional Shares of IRIDEX Corp (IRIX) - GuruFocus hu, 12 Feb 2026 08
- Zacks Initiates Coverage of Iridex With Neutral Recommendation - Nasdaq Fri, 02 Jan 2026 08
- Iridex CFO Dizon buys $1.4k in IRIX stock - Investing.com ue, 10 Feb 2026 08
- Insider Buying: Romeo Dizon Acquires Additional Shares of IRIDEX Corp (IRIX) - GuruFocus Wed, 28 Jan 2026 08
- Iridex CFO Dizon buys $5k in IRIX stock - Investing.com ue, 27 Jan 2026 08
- Iridex CFO Dizon buys $1.8k in IRIX stock - Investing.com Mon, 26 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1110 | 1399 | — | Purchase at price 1.26 per share. | DIZON ROMEO R | Chief Financial Officer | — | 2026-03-06 00:00:00 | D |
| 1 | 2200 | 2942 | — | Purchase at price 1.31 - 1.37 per share. | DIZON ROMEO R | Chief Financial Officer | — | 2026-02-17 00:00:00 | D |
| 2 | 1500 | 2145 | — | Purchase at price 1.43 per share. | DIZON ROMEO R | Chief Financial Officer | — | 2026-02-12 00:00:00 | D |
| 3 | 1000 | 1460 | — | Purchase at price 1.46 per share. | DIZON ROMEO R | Chief Financial Officer | — | 2026-02-10 00:00:00 | D |
| 4 | 2500 | 3450 | — | Purchase at price 1.38 per share. | DIZON ROMEO R | Chief Financial Officer | — | 2026-02-03 00:00:00 | D |
| 5 | 1101 | 1588 | — | Purchase at price 1.44 per share. | DIZON ROMEO R | Chief Financial Officer | — | 2026-01-29 00:00:00 | D |
| 6 | 1300 | 1898 | — | Purchase at price 1.46 per share. | DIZON ROMEO R | Chief Financial Officer | — | 2026-01-28 00:00:00 | D |
| 7 | 3385 | 5009 | — | Purchase at price 1.48 per share. | DIZON ROMEO R | Chief Financial Officer | — | 2026-01-27 00:00:00 | D |
| 8 | 1243 | 1889 | — | Purchase at price 1.52 per share. | DIZON ROMEO R | Chief Financial Officer | — | 2026-01-26 00:00:00 | D |
| 9 | 5221 | 7716 | — | Purchase at price 1.48 per share. | DIZON ROMEO R | Chief Financial Officer | — | 2026-01-23 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -6.88M | -7.97M | -6.16M | -5.83M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -8.91M | -9.57M | -7.55M | -5.22M |
| ReconciledDepreciation | 1.42M | 2.03M | 1.38M | 1.71M |
| ReconciledCostOfRevenue | 29.17M | 30.06M | 31.60M | 31.07M |
| EBITDA | -6.88M | -7.97M | -6.16M | -5.83M |
| EBIT | -8.30M | -10.01M | -7.54M | -7.53M |
| NormalizedIncome | -8.91M | -9.57M | -7.55M | -5.22M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -8.91M | -9.57M | -7.55M | -5.22M |
| TotalExpenses | 56.97M | 61.88M | 64.51M | 61.44M |
| TotalOperatingIncomeAsReported | -8.30M | -10.01M | -7.54M | -7.53M |
| DilutedAverageShares | 16.44M | 16.13M | 15.94M | 15.42M |
| BasicAverageShares | 16.44M | 16.13M | 15.94M | 15.42M |
| DilutedEPS | -0.54 | -0.59 | -0.47 | -0.34 |
| BasicEPS | -0.54 | -0.59 | -0.47 | -0.34 |
| DilutedNIAvailtoComStockholders | -8.91M | -9.57M | -7.55M | -5.22M |
| NetIncomeCommonStockholders | -8.91M | -9.57M | -7.55M | -5.22M |
| NetIncome | -8.91M | -9.57M | -7.55M | -5.22M |
| NetIncomeIncludingNoncontrollingInterests | -8.91M | -9.57M | -7.55M | -5.22M |
| NetIncomeContinuousOperations | -8.91M | -9.57M | -7.55M | -5.22M |
| TaxProvision | 68.00K | 90.00K | 65.00K | 40.00K |
| PretaxIncome | -8.84M | -9.48M | -7.48M | -5.18M |
| OtherIncomeExpense | -540.00K | 527.00K | 60.00K | 2.35M |
| OtherNonOperatingIncomeExpenses | -540.00K | 527.00K | 60.00K | 2.35M |
| OperatingIncome | -8.30M | -10.01M | -7.54M | -7.53M |
| OperatingExpense | 27.80M | 31.81M | 32.91M | 30.36M |
| ResearchAndDevelopment | 5.45M | 6.83M | 7.17M | 6.87M |
| SellingGeneralAndAdministration | 22.36M | 24.98M | 25.73M | 23.50M |
| SellingAndMarketingExpense | 12.58M | 16.24M | 18.18M | 14.64M |
| GeneralAndAdministrativeExpense | 9.78M | 8.75M | 7.56M | 8.86M |
| OtherGandA | 9.78M | 8.75M | 7.56M | 8.86M |
| GrossProfit | 19.50M | 21.81M | 25.37M | 22.83M |
| CostOfRevenue | 29.17M | 30.06M | 31.60M | 31.07M |
| TotalRevenue | 48.67M | 51.87M | 56.97M | 53.90M |
| OperatingRevenue | 48.67M | 51.87M | 56.97M | 53.90M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 16.64M | 16.25M | 15.99M | 15.88M |
| ShareIssued | 16.64M | 16.25M | 15.99M | 15.88M |
| NetDebt | 351.00K | |||
| TotalDebt | 4.64M | 2.75M | 1.77M | 2.66M |
| TangibleBookValue | -174.00K | 6.92M | 14.29M | 20.13M |
| InvestedCapital | 4.83M | 9.52M | 17.23M | 23.30M |
| WorkingCapital | 7.00M | 14.48M | 23.31M | 29.61M |
| NetTangibleAssets | -174.00K | 6.92M | 14.29M | 20.13M |
| CapitalLeaseObligations | 1.91M | 2.75M | 1.77M | 2.66M |
| CommonStockEquity | 2.10M | 9.52M | 17.23M | 23.30M |
| TotalCapitalization | 3.10M | 9.52M | 17.23M | 23.30M |
| TotalEquityGrossMinorityInterest | 2.10M | 9.52M | 17.23M | 23.30M |
| StockholdersEquity | 2.10M | 9.52M | 17.23M | 23.30M |
| GainsLossesNotAffectingRetainedEarnings | 51.00K | -52.00K | -24.00K | 45.00K |
| OtherEquityAdjustments | 51.00K | -52.00K | -24.00K | 45.00K |
| RetainedEarnings | -88.01M | -79.04M | -69.72M | -62.17M |
| AdditionalPaidInCapital | 89.88M | 88.44M | 86.80M | 85.25M |
| CapitalStock | 174.00K | 172.00K | 169.00K | 168.00K |
| CommonStock | 174.00K | 172.00K | 169.00K | 168.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 27.04M | 24.91M | 25.06M | 25.39M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.48M | 11.94M | 12.61M | 12.74M |
| OtherNonCurrentLiabilities | 314.00K | 164.00K | 26.00K | 25.00K |
| NonCurrentAccruedExpenses | 138.00K | 106.00K | 58.00K | |
| NonCurrentDeferredLiabilities | 8.35M | 10.03M | 11.74M | 10.93M |
| NonCurrentDeferredRevenue | 8.35M | 10.03M | 11.74M | 10.93M |
| LongTermDebtAndCapitalLeaseObligation | 1.81M | 1.75M | 732.00K | 1.73M |
| LongTermCapitalLeaseObligation | 811.00K | 1.75M | 732.00K | 1.73M |
| LongTermDebt | 1.00M | |||
| LongTermProvisions | 58.00K | |||
| CurrentLiabilities | 16.56M | 12.97M | 12.45M | 12.65M |
| CurrentDeferredLiabilities | 3.49M | 3.33M | 3.38M | 3.45M |
| CurrentDeferredRevenue | 3.49M | 3.33M | 3.38M | 3.45M |
| CurrentDebtAndCapitalLeaseObligation | 2.83M | 995.00K | 1.04M | 927.00K |
| CurrentCapitalLeaseObligation | 1.09M | 995.00K | 1.04M | 927.00K |
| CurrentDebt | 1.73M | |||
| OtherCurrentBorrowings | 1.73M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.67M | 1.62M | 2.45M | 3.19M |
| CurrentProvisions | 100.00K | |||
| PayablesAndAccruedExpenses | 8.57M | 7.03M | 5.59M | 5.07M |
| CurrentAccruedExpenses | 770.00K | 2.06M | 1.54M | 1.50M |
| Payables | 7.80M | 4.98M | 4.04M | 3.57M |
| OtherPayable | 57.00K | 149.00K | 106.00K | 97.00K |
| DuetoRelatedPartiesCurrent | 609.00K | 228.00K | 15.00K | 627.00K |
| TotalTaxPayable | 150.00K | 100.00K | 65.00K | 73.00K |
| AccountsPayable | 6.99M | 4.50M | 3.86M | 2.77M |
| TotalAssets | 29.14M | 34.44M | 42.29M | 48.69M |
| TotalNonCurrentAssets | 5.57M | 6.99M | 6.52M | 6.43M |
| OtherNonCurrentAssets | 1.39M | 1.40M | 1.46M | 271.00K |
| GoodwillAndOtherIntangibleAssets | 2.27M | 2.61M | 2.94M | 3.17M |
| OtherIntangibleAssets | 1.31M | 1.64M | 1.98M | 2.21M |
| Goodwill | 965.00K | 965.00K | 965.00K | 965.00K |
| NetPPE | 1.91M | 2.98M | 2.13M | 2.99M |
| AccumulatedDepreciation | -13.98M | -13.74M | -13.56M | -13.39M |
| GrossPPE | 15.89M | 16.72M | 15.69M | 16.38M |
| Leases | 2.49M | 2.49M | 2.49M | 2.45M |
| OtherProperties | 13.40M | 14.23M | 13.19M | 13.93M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 23.56M | 27.45M | 35.77M | 42.25M |
| OtherCurrentAssets | 1.96M | 856.00K | 1.47M | 1.07M |
| PrepaidAssets | 1.07M | |||
| Inventory | 10.82M | 9.91M | 10.61M | 7.61M |
| FinishedGoods | 6.58M | 4.46M | 4.47M | 3.48M |
| WorkInProcess | 0.00 | 156.00K | 320.00K | 201.00K |
| RawMaterials | 4.24M | 5.29M | 5.82M | 3.94M |
| Receivables | 8.39M | 9.65M | 9.77M | 9.72M |
| DuefromRelatedPartiesCurrent | 2.44M | 2.93M | 3.54M | 3.11M |
| AccountsReceivable | 5.95M | 6.73M | 6.23M | 6.61M |
| AllowanceForDoubtfulAccountsReceivable | -259.00K | -146.00K | -390.00K | -268.00K |
| GrossAccountsReceivable | 6.21M | 6.87M | 6.62M | 6.88M |
| CashCashEquivalentsAndShortTermInvestments | 2.39M | 7.03M | 13.92M | 23.85M |
| CashAndCashEquivalents | 2.39M | 7.03M | 13.92M | 23.85M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.30M | -6.85M | -9.80M | 8.00M |
| RepaymentOfDebt | -218.00K | 0.00 | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 3.37M | 0.00 | 0.00 | 9.88M |
| CapitalExpenditure | -13.00K | -109.00K | -286.00K | -213.00K |
| IncomeTaxPaidSupplementalData | 15.00K | 53.00K | 73.00K | 15.00K |
| EndCashPosition | 2.39M | 7.03M | 13.92M | 23.85M |
| BeginningCashPosition | 7.03M | 13.92M | 23.85M | 11.63M |
| EffectOfExchangeRateChanges | 46.00K | -29.00K | -52.00K | 99.00K |
| ChangesInCash | -4.69M | -6.86M | -9.88M | 12.13M |
| FinancingCashFlow | 2.60M | -5.00K | -73.00K | 9.47M |
| CashFlowFromContinuingFinancingActivities | 2.60M | -5.00K | -73.00K | 9.47M |
| NetOtherFinancingCharges | -551.00K | -87.00K | -94.00K | -629.00K |
| ProceedsFromStockOptionExercised | 4.00K | 82.00K | 21.00K | 217.00K |
| NetCommonStockIssuance | 3.37M | 0.00 | 0.00 | 9.88M |
| CommonStockIssuance | 3.37M | 0.00 | 0.00 | 9.88M |
| NetIssuancePaymentsOfDebt | -218.00K | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | -218.00K | 0.00 | 0.00 | |
| LongTermDebtPayments | -218.00K | 0.00 | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -13.00K | -109.00K | -286.00K | -5.56M |
| CashFlowFromContinuingInvestingActivities | -13.00K | -109.00K | -286.00K | -5.56M |
| NetBusinessPurchaseAndSale | 0.00 | -5.34M | ||
| PurchaseOfBusiness | 0.00 | -5.34M | ||
| NetPPEPurchaseAndSale | -13.00K | -109.00K | -286.00K | -213.00K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -13.00K | -109.00K | -286.00K | -213.00K |
| OperatingCashFlow | -7.29M | -6.75M | -9.52M | 8.22M |
| CashFlowFromContinuingOperatingActivities | -7.29M | -6.75M | -9.52M | 8.22M |
| ChangeInWorkingCapital | -1.37M | -857.00K | -5.16M | 12.56M |
| ChangeInOtherWorkingCapital | -1.90M | -1.72M | 868.00K | 12.06M |
| ChangeInOtherCurrentLiabilities | -111.00K | -794.00K | -1.01M | -791.00K |
| ChangeInOtherCurrentAssets | 2.00K | -427.00K | -1.19M | -143.00K |
| ChangeInPayablesAndAccruedExpense | 1.40M | 473.00K | -179.00K | 3.98M |
| ChangeInAccruedExpense | -1.47M | -381.00K | -653.00K | 1.73M |
| ChangeInPayable | 2.87M | 854.00K | 474.00K | 2.25M |
| ChangeInAccountPayable | 2.49M | 641.00K | 1.09M | 1.62M |
| ChangeInPrepaidAssets | -1.11M | 612.00K | -397.00K | -341.00K |
| ChangeInInventory | -911.00K | 644.00K | -3.02M | 268.00K |
| ChangeInReceivables | 1.26M | 358.00K | -237.00K | -2.47M |
| ChangesInAccountReceivables | 776.00K | -254.00K | 196.00K | 639.00K |
| OtherNonCashItems | 328.00K | |||
| StockBasedCompensation | 1.24M | 1.65M | 1.62M | 1.63M |
| ProvisionandWriteOffofAssets | 0.00 | 187.00K | 37.00K | |
| DepreciationAmortizationDepletion | 1.42M | 2.03M | 1.38M | 1.71M |
| DepreciationAndAmortization | 1.42M | 2.03M | 1.38M | 1.71M |
| Depreciation | 1.42M | 2.03M | 1.38M | 1.71M |
| OperatingGainsLosses | -2.49M | |||
| GainLossOnSaleOfPPE | 0.00 | 3.00K | ||
| NetIncomeFromContinuingOperations | -8.91M | -9.57M | -7.55M | -5.22M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IRIX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|